This move is archived. Current quotes and coverage live on the stock page.
Get BLCO alerts:
Bausch + Lomb Corp faces a challenging day on the TSX, with shares down 2.50%.
In the latest trading session, Bausch + Lomb Corp (BLCO.TO) saw its stock price drop by 2.50%, closing at CA$21.10. This decline comes despite recent product launches aimed at strengthening its position in the eye care sector.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.52B
52W high
$25.70
52W low
$19.36
1W change
-1.89%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to rise 3.0% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.10
+3.0% Upside
Current Price
C$24.36
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
22.3%
Annualized
90-Day Vol
26.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$29.12
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$25.85 | C$23.94 – C$27.92 |
| 60 trading days | C$27.44 | C$24.61 – C$30.59 |
| 90 trading days | C$29.12 | C$25.49 – C$33.27 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Bausch + Lomb's recent product launches may not be enough to offset the current market sentiment affecting its stock price.
Stock down 2.50% in one trading day
Bausch + Lomb's market cap stands at CA$7.66 billion, reflecting investor sentiment amid ongoing challenges.
Bull case
The launch of new products like Blink® Triple Care Preservative Free eye drops could eventually boost sales and market share, especially in the growing dry eye segment.
Bear case
However, the recent stock decline raises concerns about profitability and competition, which could limit future growth prospects.
Recent Performance Overview
Advertisement
Bausch + Lomb Corp's stock has taken a hit, closing at CA$21.10 after a 2.50% drop in the last trading session. This decline raises questions about the company's ability to maintain investor confidence amidst competitive pressures.
Product Launch and Market Reaction
Despite the recent launch of Blink® Triple Care Preservative Free eye drops, aimed at capturing a larger share of the dry eye market, the stock's performance suggests that investors are skeptical about the company's growth trajectory. The product's success will be critical in determining whether it can increase revenue in a competitive landscape.
Looking Ahead
As Bausch + Lomb navigates its current challenges, investors will need to keep an eye on upcoming earnings reports and market trends in the eye care sector. The company's ability to innovate and respond to market demands will be crucial for regaining investor trust and improving stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
